Study wrapper · #1006
Clinical Potential of GIP in Type 2 Diabetes and Obesity.
Nauck M, Gribble F, Reimann F, et al. Diabetes care. 2026.
DOI: 10.2337/dci25-0141PubMed: 41973737
Editor's note
A mechanistic review that positions tirzepatide as the most potent incretin-based agent to date and explores the contribution of GIP receptor signaling to its metabolic effects. Tirzepatide is central to the discussion, though the review focuses on incretin biology rather than reporting new trial data. It is a solid background reference on how dual incretin agonism has been studied in metabolic disease.
Plain-language abstract
This review examines the biology of GIP receptor signaling and its role in metabolic pharmacology, using tirzepatide as the leading example of a dual GLP-1/GIP receptor agonist studied for type 2 diabetes and obesity. It discusses how GIP receptor activity may contribute to future drug development.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillarsn=——2026